Granules India, announced its financial results for the quarter ended December 31, 2024.

Revenue from operations of Q3FY25 stood at Rs 11,377 million, a decline of 2 per cent YoY. Revenue share from North America increased to 77 per cent in Q3 FY25, compared to 66 per cent in Q3 FY24. Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 76 per cent, 12 per cent and 12 per cent of revenue from operations respectively for Q3FY25. Return on Capital Employed for Q3 FY 25 is at 16.4 per cent as compared to 15.3 per cent for Q3 FY 24. Net debt stood at Rs 8,289 million and net debt to EBITDA ratio was 0.90.

Dr Krishna Prasad Chigurupati, CMD, Granules India said, “We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur. Progress on our greenfield formulation expansion at GLS remains on track, reinforcing our capabilities and driving future growth.”